| 1 |
Luiz MT, Dutra JAP, De Araújo JTC, Di Filippo LD, Duarte JL, Chorilli M. Functionalization of Nanosystems in Cancer Treatment. Cancer Nanotechnology 2023. [DOI: 10.1007/978-3-031-17831-3_3] [Reference Citation Analysis]
|
| 2 |
Jiang Z, Zhang W, Zhang J, Liu T, Xing J, Zhang H, Tang D. Nanomaterial-Based Drug Delivery Systems: A New Weapon for Cancer Immunotherapy. Int J Nanomedicine 2022;17:4677-96. [PMID: 36211025 DOI: 10.2147/IJN.S376216] [Reference Citation Analysis]
|
| 3 |
Flores de los Rios PA, Casañas Pimentel RG, San Martín Martínez E. Nanodrugs against cancer: biological considerations in its redesign. International Journal of Polymeric Materials and Polymeric Biomaterials. [DOI: 10.1080/00914037.2022.2097680] [Reference Citation Analysis]
|
| 4 |
Zhu R, Zhang F, Peng Y, Xie T, Wang Y, Lan Y. Current Progress in Cancer Treatment Using Nanomaterials. Front Oncol 2022;12:930125. [DOI: 10.3389/fonc.2022.930125] [Reference Citation Analysis]
|
| 5 |
Spreen H, Barth C, Keuter L, Mulac D, Humpf H, Langer K. Tuning the protein corona of PLGA nanoparticles: Characterization of trastuzumab adsorption behavior and its cellular interaction with breast cancer cell lines. Journal of Drug Delivery Science and Technology 2022. [DOI: 10.1016/j.jddst.2022.103543] [Reference Citation Analysis]
|
| 6 |
Mainini F, De Santis F, Fucà G, Di Nicola M, Rivoltini L, Eccles M. Nanobiotechnology and Immunotherapy: Two Powerful and Cooperative Allies against Cancer. Cancers (Basel) 2021;13:3765. [PMID: 34359665 DOI: 10.3390/cancers13153765] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 7 |
Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol 2021;14:85. [PMID: 34059100 DOI: 10.1186/s13045-021-01096-0] [Cited by in Crossref: 88] [Cited by in F6Publishing: 103] [Article Influence: 44.0] [Reference Citation Analysis]
|
| 8 |
Nieto C, Vega MA, Martín Del Valle E. Nature-Inspired Nanoparticles as Paclitaxel Targeted Carrier for the Treatment of HER2-Positive Breast Cancer. Cancers (Basel) 2021;13:2526. [PMID: 34064007 DOI: 10.3390/cancers13112526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 9 |
Liu F, Wu H. Identification of Prognostic Biomarkers and Molecular Targets Among JAK Family in Breast Cancer. J Inflamm Res 2021;14:97-114. [PMID: 33469338 DOI: 10.2147/JIR.S284889] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Kifle ZD, Tadele M, Alemu E, Gedamu T, Ayele AG. A recent development of new therapeutic agents and novel drug targets for cancer treatment. SAGE Open Medicine 2021;9:205031212110670. [DOI: 10.1177/20503121211067083] [Reference Citation Analysis]
|
